Biotech

All Articles

Lykos are going to ask FDA to rethink its own decision adhering to being rejected of MDMA therapy for post-traumatic stress disorder

.Following a bad showing for Lykos Rehabs' MDMA applicant for trauma at a recent FDA advising commit...

AN 2 halves headcount, ceases stage 3 trial after data disappoint

.AN2 Therapeutics is actually reassessing its business in response to lackluster midphase data, prom...

Merck pays for $700M for bispecific, spying autoimmune position and opportunity to challenge Amgen in cancer cells

.Merck &amp Co. is actually paying $700 million beforehand to challenge Amgen in a blood cancer mark...

Gilead spends J&ampJ $320M to leave licensing package for seladelpar

.With Gilead Sciences about to an FDA choice for its liver ailment medication seladelpar, the firm h...

' All palms on deck' at Lilly as peers target obesity market

.Chief executive officer David Ricks can easily see the business setting up tents at basecamp respon...

Entero giving up staff, vacating workplace and pausing R&ampD

.Bed mattress Liquidators has switched Entero Therapies white as a slab. The creditor got Entero to ...

Exelixis goes down ADC after choosing it's no match for Tivdak

.Exelixis is actually quiting on its tissue aspect (TF)- targeting antibody-drug conjugate after wra...

Relay dislikes SHP2 inhibitor after Genentech leaves behind

.3 full weeks after Roche's Genentech system walked away from an SHP2 inhibitor treaty, Relay Rehab ...

Stoke's Dravet syndrome med discharged of partial professional hold

.Stoke Therapeutics' Dravet disorder medicine has been freed from a partial hold, getting rid of the...

Fierce Biotech's Gabrielle Masson shows Brutal 15 at NYSE

.Fierce Biotech Partner Publisher Gabrielle Masson offered the 2024 class of Tough 15 victors on the...